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Background: Advanced cancer patients experience considerable symptoms, problems, and needs. Early referral of
these patients to specialized palliative care (SPC) could offer improvements. The Danish Palliative Care Trial
(DanPaCT) investigates whether patients with metastatic cancer will benefit from being referred to ‘early SPC’.
DanPaCT is a multicenter, parallel-group, superiority clinical trial with 1:1 randomization. The planned sample size
was 300 patients. The primary data collection for DanPaCT is finished. To prevent outcome reporting bias, selective
reporting, and data-driven results, we present a detailed statistical analysis plan (SAP) for DanPaCT here.
Results: This SAP provides detailed descriptions of the statistical analyses of the primary and secondary outcomes in
DanPaCT. The primary outcome is the change in the patient’s ‘primary need’. The ‘primary need’ is a patient-individualised
outcome representing the score of the symptom or problem that had the highest intensity out of seven at baseline
assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30). Secondary outcomes are the seven scales that are represented in the primary outcome, but each
scale evaluated individually for all patients, and survival. The detailed description includes chosen significance
levels, models for multiple imputations, sensitivity analyses and blinding. In addition, we discuss the patient-individualized
primary outcome, blinding, missing data, multiplicity and the risk of bias.
Conclusions: Only few trials have investigated the effects of SPC. To our knowledge DanPaCT is the first trial to
investigate screening based ‘early SPC’ for patients with metastatic cancer from a broad spectrum of cancer diagnosis.
Trial registration: Clinicaltrials.gov identifier: NCT01348048 (May 2011).
Keywords: palliative care, advanced cancer, randomized clinical trial, quality of life, needs assessment, patient
satisfaction, cost-effectiveness, data interpretation, statistical analysis plan, protocolUpdate
Introduction
The Danish Palliative Care Trial (DanPaCT) investigates the
effects of early specialized palliative care (SPC) for patients
with advanced cancer. The trial is a multicenter, parallel-
group, superiority clinical trial with 1:1 randomization con-
ducted at six Danish SPC centers. A design and protocol
paper describing the design of DanPaCT has previously
been published [1].* Correspondence: anna.thit.johnsen@regionh.dk
1The Research Unit, Department of Palliative Medicine, Bispebjerg Hospital,
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Dedication waiver (http://creativecommons.or
unless otherwise stated.This paper describes the detailed statistical analysis
plan (SAP) for DanPaCT. In accordance with good clin-
ical practice [2] and to avoid outcome reporting bias [3],
this SAP was developed before the database was locked
and data analysis was initiated. The last patient in the
DanPaCT was randomized on 13 December 2013. The
last follow-up questionnaire was sent out in March
2014. Data on survival will be retrieved in June 2014.
The DanPaCT project group agreed on this SAP on 14
May 2014, and an outline of this SAP was posted on
clinicaltrials.gov in June 2014.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In DanPaCT, consecutive patients from departments of
oncology were randomized to standard treatment plus
SPC (the experimental group) versus standard treatment
(the control group). Inclusion criteria were a) metastatic
cancer, b) 18 years or older, c) no prior contact with
SPC, and d) a palliative need according to the screening
questionnaire. Patients who were eligible according to
the inclusion criteria and who consented to participate
after having received written and verbal information
about the trial were randomized. Patients who were ran-
domized to the experimental group were subsequently
referred to the relevant SPC center.
The screening questionnaire constitutes the entry data
(baseline), and patients receive similar questionnaires at
the three- and eight-week follow-up. For the experimen-
tal group the three-week follow-up was sent three weeks
after their first contact with SPC. For the control group
it was sent at a matching time. The eight-week follow-
up was sent five weeks after the three-week follow-up
(see Figure 1). The questionnaires consist of the European
Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30) [4],
a questionnaire measuring the patients’ satisfaction with
the health care system, the FAMCARE-P16 scale [5], and
the Hospital Anxiety and Depression Scale (HADS)
[6]. In addition, data on survival and healthcare costs
will be collected. The primary outcome is reduction in
the patient’s primary need and secondary outcomes areFigure 1 Time points in the Danish Palliative Care Trial (DanPaCT).the seven scales that are represented in the primary
outcome, but each scale is evaluated individually for
all patients (see sections on primary and secondary
outcomes).
The protocol has been approved by the local regional eth-
ics committee (the Ethics Committee for the Capital Region,
Denmark; journal number H-3-2010-144) and the Danish
Data Protection Agency (journal number BBH-2011-05
DanPaCT) and is registered at www.clinicaltrials.gov
(NCT01348048).
The primary outcome and sample size
The primary outcome is the change in the patient’s pri-
mary need. It is estimated as the difference between the
experimental and the control group in the change from
baseline to the weighted mean of the three- and eight-
week follow-up measured as area under the curve (AUC)
for the EORTC QLQ-C30 scale score that constitutes the
primary need.
The primary need is the one of the following seven
scales from the EORTC QLQ-C30 that had the highest
score (representing most symptom intensity or most re-
duced function) at baseline: physical function, role function,
emotional function, nausea and vomiting, pain, dyspnea, or
lack of appetite. The primary outcome is thus a patient-
individualized outcome representing the score on one of
seven different scales (for example, patients having the pain-
scale as the scale with the highest intensity at baseline will
have pain as their primary outcome). If a patient had the
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domly assigned as the primary need by the Copenhagen
Trial Unit (CTU) based on a simple randomization between
the needs.
We know from previous studies that the standard devi-
ation (SD) for a difference between repeated measurements
(three weeks apart) in the EORTC QLQ-C30 ranges from
15 for the primary needs with the lowest SD to 22 for the
one with the highest SD (unpublished data of patients re-
ferred to department of Palliative Medicine, Bispebjerg
Hospital collected by MAP, PS, LP, MG from the author
list). Therefore, we assume that the primary outcome has
an SD of 20 points in the present trial. We wish to be
able to detect a minimal relevant difference of 7.5
points (a difference between 5 and 10 is normally judged
clinically significant for scales in the EORTC QLQ-C30
[7]). With a risk of type I error of 0.05 for two-sided confi-
dence intervals and type II error of 0.10, we need 150 pa-
tients in each intervention group (that is, a total of 300
patients, or about 50 from each of the six centers).
Secondary outcomes and power
The secondary outcomes are all of the scales evaluated
to determine the primary need (that is, physical function,
role function, emotional function, nausea and vomiting,
pain, dyspnea, and lack of appetite). Each scale will be
analyzed individually for all patients. We calculated the
power based on the following premises: a) a sample size
of 300 participants (150 in each group); b) a wish to detect
a clinically relevant difference on the AUC that corresponds
to a difference of 7.5 points on a 0 to 100-point scale; c) an
SD expected to be 20 points; d) alpha set to 0.01 (conserva-
tive to protect against multiplicity); and e) an expected cor-
relation between baseline and the eight-week follow-up of
0.4, between baseline and the three-week follow-up of 0.6,
and between the three- and eight-week follow-up of 0.7.
With these premises, we have a power of 83% for each of
these secondary outcomes (that is, a risk of type II
error of 17%).
Survival is also a secondary outcome. For this power
calculation, we used data from the Temel et al. trial [8].
Although the Temel et al. trial only included lung cancer
patients and only included patients who were recently
diagnosed with metastatic cancer, it is reasonable to as-
sume similarity between the two trials regarding survival
although we include many different metastatic cancer
diagnoses. Temel et al. found a hazard ratio for death of
1.7 and a median survival in the control group of 8.9 months.
Using these figures, and with an actual recruitment time of
30 months (May 2011 to December 2013), a six-month
follow-up on survival (as in the present trial), a sample size
of 150 patients in each group, and then, with an alpha
of 0.01, we will have a power of 88% (that is, a risk of
type II error of 12%).Exploratory outcomes
The trial has the following exploratory outcomes:
1. The remaining scales from EORTC QLQ-C30 [4]
( cognitive function, social function, overall quality of
life, fatigue, insomnia, constipation, diarrhea, and
financial difficulties).
2. Anxiety and depression measured with the Hospital
Anxiety and Depression Scale (HADS) [5].
3. Satisfaction with the health care system measured
with the FAMCARE-P16 questionnaire [6].
4. Health care costs per week from the start of the trial
to minimum three months after the end of the
intervention (including at least number of days of
hospitalization, ambulatory visits, home visits,
emergency visits and general practitioner (GP)
visits).
Serious adverse events are defined as hospitalizations
and deaths from the time of randomization to the eight-
week follow-up. Serious adverse events will be reported
in the primary publication. The remaining explorative
outcomes are not expected to be part of the primary
publication. However, they will all be published in subse-
quent publications.
Descriptive variables
For background variables and variables describing the
trial, see Table 1. The distribution of these variables will
be given for both intervention groups, but the potential
difference between groups will not be significance tested
to avoid unnecessary testing [9].
We also collect detailed data on the pattern of the ex-
perimental groups’ contact with the SPCs: telephone con-
tacts, home-visits, consultations with other professions
(psychologists, physiotherapists, social workers, occupa-
tional therapists and so forth), multidisciplinary confer-
ences, and description of SPC start. We further collect
data on hospitalizations and outpatients’ contacts with the
departments of oncology for both groups. In addition, we
collect detailed information on the interventions received
in the SPCs and in the departments of oncology. Except
from a brief description of SPC contacts, these data will
not be part of the primary publication.
Plan of statistical analysis
Significance levels
All tests will be two-tailed. For the primary outcome, the
risk of type I error is set to 5% (that is, a significance
level of P <0.05). If the primary outcome is significant,
we will calculate the Bayes factor of the primary out-
come using the data from the sample size calculation for
the trial as described by Jakobsen et al. [10]. The exact
procedure can be seen in the supplement to the paper
Table 1 Descriptive variables and their definitions
Variable Definition Assessed by/assessed from
Baseline variables
Sex The Danish Civil Registration System
(called CPR in Danish) which depict
sex and age
Age The Danish Civil Registration
System (called CPR in Danish) which
depict sex and age
Cancer Project nurse
Receiving treatment (yes/no) Whether the patient is receiving active anti-neoplastic
treatment at the time of randomization
Project nurse
Education Questionnaire, self-assessment
WHO performance score Project nurse
Time since diagnosed with
cancer stage four
Assessment based on the TNM (tumor, node, metastasis)
system. First time it is documented that the patient has
stage four cancer. Staging is updated, so a patient
diagnosed with stage two and developing distant
metastases at a later time is considered as having stage
four when the metastases are discovered
Doctors or students with at least
a bachelor degree in medicine
Time since diagnosed with
primary cancer
Project nurse
Study descriptive variables
Center There are six centers included in the study
Primary need Each patient is randomized for one out of seven potential
primary needs (please see article text)
Questionnaire, self-assessment
Use of health care services
outside the hospital
Use of for example, psychologist, physiotherapist or other
health care services outside the hospital in the eight-week
intervention period
Questionnaire, self-assessment
Cross-over Patients from the control group receiving at least one
physical contact with specialized palliative care (SPC)
within the study period
Students
Protocol violations Patients from the intervention group not receiving at least
one physical contact with the SPC within the study period
Students
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provided at the end of the reference. A low Bayes factor
(for example, less than 0.1) and a low P value (for example,
less than 0.05) will correspond to a high probability of an
intervention effect equivalent to or larger than the clinical
relevant effect used in the sample size calculation. If a
Bayes factor is calculated ( because we have a significant
primary outcome), the results of this calculation will be
used to modify our interpretation of the P value and
conclusion.
If the change in the primary outcome is at least 7.5
points better (on a 0 to 100-point scale) in the experi-
mental group than in the control group, we believe this
to be clinically relevant [7,11,12]. However, all results
from unblinded trials should be critically evaluated for
bias, and this should be taken into account when inter-
preting results [13,14]. If the experimental group has
shorter survival or more adverse events, then this must,
of course, also be included in the interpretation of the
clinical relevance of SPC.As we have eight secondary outcomes, we adjust the
significance levels to P <0.01 to control the familywise
(or cumulative) type I error due to multiplicity [2,15,16].
We use an interpretation of our P values for the second-
ary outcomes in accordance with the following (if the ef-
fect of the intervention is in the expected direction):
1. P ≥0.05: The trial results could not demonstrate an
effect of the experimental intervention on the
secondary outcome.
2. 0.01 < P <0.05: The trial results indicate that there
may be a positive effect of the experimental
intervention on the secondary outcome. However,
the indication is not strong.
3. 0.001 < P <0.01: The trial results indicate that there
may be a positive effect of the experimental
intervention on the secondary outcome.
4. P <0.001: The trial results strongly indicate that
there may be a positive effect of the experimental
intervention on the secondary outcome.
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vided, but it will be made clear that the analyses are ex-
ploratory and that we have reported comparisons of one
primary and eight secondary outcomes.
Analysis of the primary outcome
The primary outcome analysis will be a modified Intention-
to-treat (ITT) analysis. Patients who withdrew consent after
randomization, who were randomized by mistake and did
not fulfil our inclusion criteria, or who were not alive at the
time of the follow-ups, will be excluded from the analysis.
All exclusions will be shown in the Consolidated Standards
of Reporting Trials (CONSORT) flowchart of patient
participation.
In the primary outcome analysis we will use non-
monotone multiple imputation for nonresponders if there
are more than 5% missing outcomes [17]. The imputations
are multivariate normal imputations, and we will use SAS
statistical software version 9.3. We use the standard SAS
procedure for multiple imputations using the fully condi-
tional specification (FCS) statement [18]. In total, we will
make 20 different datasets with imputation based on a re-
gression model using predictive mean matching [17,18].
Predictive mean matching (PMM) will be implemented
with ‘regPMM’ having five ‘people’ in the matching pool
(which is the default in SAS). In the model, we will include
the following variables if they are predictors of the out-
come or of having a missing answer (P <0.05 in a univari-
ate model and less than 5% missing on the variable in
question): the value of the primary outcome in the base-
line, the three-week follow-up, and the eight-week follow-
up, intervention group (experimental or control), age, sex,
The World Health Organizations’ (WHO) performance
score, diagnosis, time since diagnoses with metastatic can-
cer, receiving treatment, and center. It is recommended
only to use variables that are (strong) predictors of the out-
come or of having missing answers in the model; other-
wise, the variables will only introduce noise [16,19]. When
reporting the results, we will, according to guidelines, re-
port on the extent and distribution of missing data [20].
The primary outcome analysis will be a multiple re-
gression adjusted for the stratification variable using a
fixed effect [21]. The primary need is used as a group-
variable when included as an adjusting covariate (thus,
the score on the primary need is not used).
We expect our primary outcome to be normally dis-
tributed as differences are often normally distributed
[19]. However, if that is not the case, we will try to trans-
form data into a normal distribution, which is often pos-
sible. If this is not possible we will use models of other
distributions. If this is not possible, we will use nonpara-
metric tests such as the van Elteren [22].
In accordance with the design of the trial, some time
elapsed from the baseline questionnaire until the patientwas randomized and then again, from randomization to the
experimental groups’ first contact with SPC (see Figure 1).
The timing of the three-week follow-up was dependent on
the experimental groups’ first contact with SPC. An equiva-
lent time was added to the control group, so that both
groups received the follow-ups at the same time. The me-
dian time from randomization to the three- and eight-week
follow-up for each group will be used to calculate the AUC
for both groups.Sensitivity and explorative analyses of the primary outcome
Sensitivity analyses will be made to test the robustness
of the conclusion according to the following rules: a) they
should address the same questions as the primary analysis;
b) it should be a possibility that they will arrive at another
conclusion; and c) if another conclusion is reached, there
shall be genuine uncertainty of which one is correct [23].
A description of the types of sensitivity analyses can be
seen in Table 2.
In addition, to test if the effect of SPC is the same re-
gardless of what the primary need is, we will treat the
trial as seven different trials - one trial for each need
included in the primary outcome - and carry out a
random-effects meta-analysis on the results of each
primary need. This analysis will be considered an ex-
plorative analysis of the primary outcome, and the re-
sults of this analysis will be included when discussing
the primary outcome of the trial.Analysis of secondary outcomes
The analyses of the seven scales from EORTC QLQ-C30
will use all the same principles as described for the pri-
mary outcome including the sensitivity analyses. Survival
will be analyzed using a Kaplan-Meier plot. Patients who
are alive three months after the end of data-collection
will be censored on this date. A Cox regression will be
made, adjusted for the stratification variable. A sensitiv-
ity analysis will be made, adjusting for the same covari-
ates, with the same criteria as in the first sensitivity
analysis of the primary outcome.Exploratory outcomes and subgroup analyses
For serious adverse events, we report the number of
hospitalizations and deaths in the eight-week trial period.
The analyses of the other exploratory outcomes will not
be dealt with in detail here. The overall principles regard-
ing questionnaire data (the remaining scales from EORTC
QLQ-C30, HADS and FAMCARE-P16) are that they will
be analyzed as complete case analyses and interpreted ac-
cordingly. Any subgroup analyses will be exploratory, and
it will be stated in the papers that they were post hoc sub-
group analyses.
Table 2 Description of the sensitivity analyses that will be made for the primary outcome
Imputations Adjusted Area under the
curve (AUC)
Intention-to-treat (ITT) principle
Fully adjusted
analysis
Yes, as in
the primary
analysis
Adjusted for covariates (center, WHO
performance status, time since the patient
was diagnosed with metastases, treatment
status, sex, age, diagnosis and education)
that are associated with the primary
outcome (P <0.10 in a univariate test) and
where missing <5%
Yes, as in the
primary analysis
Modified ITT analysis as in the
primary analysis.
Complete case
analysis
No Yes, as in the primary analysis Yes, as in the
primary analysis
Violated, no imputations for patients who
did not respond to the questionnaire.
Analysis may be biased
Model for repeated
measurement
analysis
Yes, as in
the primary
analysis
Yes, as in the primary analysis No. The three- and
eight-week follow-ups
are assessed individually
Modified ITT analysis as in the primary
analysis
Per protocol
analysis
Yes, as in
the primary
analysis
Yes, as in the primary analysis Yes, as in the primary
analysis
Violated, excluding patients who did not
receive the experimental intervention
(defined as at least one contact to the SPC
team). The analysis thus only describes the
effect of the intervention on those complying
with the intervention, which is a subgroup of
patients
Including patients
who died
Yes, as in
the primary
analysis
Yes, as in the primary analysis Yes, as in the primary
analysis
ITT analysis. Multiple imputations for
patients who do not respond or die
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Patients and questionnaires
Patients could obviously not be blinded to intervention.
However, the specific primary outcome of the trial was
not revealed to them. In the patient information, it was
written that: ‘the aim of the trial is to investigate if it
helps people who have reported symptoms and/or prob-
lems to be referred to specialized palliative care. In
addition it is investigated whether it has consequences
for their satisfaction with treatment and care, their sur-
vival and healthcare costs’.
All questionnaires were double-entered and compared
by students who were not investigators.
Register data
Survival will be retrieved from the Danish Civil Registra-
tion System (called the CPR-register), and serious ad-
verse events and contacts with the health care system
will be retrieved from a Danish Patient Registry (called
Landspatientregistret in Danish).
All medical records for the patients have been re-
trieved for the period from randomization to the eight-
week follow-up. The medical records will be split into
the medical records from the department of oncology
and those from the palliative care team. Hereafter, the
medical records will be blinded by students who will
delete all paragraphs that can be related to assignment
(for example, deleting sentences such as, ‘the patient
expressed satisfaction with the palliative care team’).When the medical records have been blinded they will
be assigned new identification numbers. Students code
the medical records for interventions and contacts while
the medical records are in a blinded format.
Data-management and analyses
Data management will be done by ATJ. All decisions will
be recorded in a log book, and all more vital decisions
will be made in consultation with at least two members
of the investigator group (one of whom is the principle
investigator).
Analyses will be made by MAP, who is blinded to the
identity of the two intervention groups, which will be
denoted Y and X (or vice versa). Results will be pre-
sented blinded in the same way for the investigators, and
conclusions regarding the results will be drawn by the
investigators and written down while the interventions
are still blinded. The blinding will not be broken before
all analyses of primary and secondary outcomes have
been conducted.
Discussion
The primary outcome: a patient-individualized outcome
Our primary outcome is a patient-individualized out-
come. It consists of one of seven different EORTC QLQ-
C30 scales, and each patient is only represented with
one of the scales. The scale that represents each patient
reflects the patient’s main symptom or problem. The great
advantage of this primary outcome is that all patients are
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For example, for a patient not having any constipation,
improvement in the constipation score cannot be ex-
pected even with optimal palliative care. Therefore, this
approach prevents the ‘dilution’ of effect arising from in-
clusion of clinically less relevant measurements (including
symptoms/problems the patients do not have).
Clinical trials testing interventions in heterogeneous
patient populations may choose to select a single, com-
mon symptom (e.g., pain) as the primary outcome but
this approach may be problematic if many of the pa-
tients do not have that particular symptom. Alterna-
tively, a global quality of life index (a sum of the score
on several different symptom/problem scales such as
FACT-L [8]) can be used with the expectation that this
measures a range of relevant aspects. However, a global
index may still be problematic if many of the items
measure symptoms/problems that are not present in the
patients. In both cases the effect of the intervention may
be diluted in the measurement, leading to the risk of
false negative results and problems with interpretation.
In relation to specialized palliative care, it is well-known
that patients are heterogeneous as they are referred for
many different problems, e.g., pain, constipation, depres-
sion, anxiety, existential, or psychosocial problems. We
cannot expect an effect on all symptoms/problems when
the patients only experience some of them. We therefore
use a patient individualized outcome in DanPaCT. To fur-
ther explain the point, consider the following hypothetical
example. In a trial two subgroups of patients were in-
cluded. About half of the patients had arm fractures and
the other half had leg fractures. If a primary outcome fo-
cusing on arm mobility were used, only half of the patients
could be expected to improve. Alternatively, a 'global
index' of arm and leg mobility could be used but again this
would be introducing noise (and hence dilute effect) be-
cause even the arm patients benefiting from the treatment
would probably not improve on the items measuring leg
mobility. Another approach would be an individualized
outcome like the one used in DanPaCT: arm fracture pa-
tients were evaluated with the arm mobility score and vice
versa. The trial would have one outcome (change in the
mobility related to the site of fracture), and hence all pa-
tients would be evaluated in a relevant way, thus minimis-
ing noise in measurement.
One could also argue that we should have made seven
different studies - one for each of the scales in the pri-
mary outcome. However, this would be highly expensive
and time-consuming. In addition, it is the basic assump-
tion in the present trial that SPC can relieve many differ-
ent symptoms or problems if they are important for the
patient or causing the patient distress, and therefore, it
is relevant with a trial investigating the combination of
these.The primary outcome and ITT considerations
The primary analysis is a modified ITT analysis as we will
exclude those who a) withdrew consent, b) were mis-
takenly randomized or c) died before the eight-week
follow-up assessment. It will be clear from the CONSORT
diagram how many patients were excluded for each rea-
son. Only very few patients withdrew consent, and there-
fore. this is not likely to cause any bias. Likewise only few
patients were mistakenly randomized, and they were re-
moved based on objective criteria, regardless of group allo-
cation and no matter what happened after inclusion.
When this is the case, it is often considered to be without
risk of bias to remove them from the analysis [24].
One can ask whether it is the correct decision to leave
out those who died from the primary analysis, as this
may be considered a violation to the ITT principle. The
main argument for doing so is that it does not make
sense to discuss the quality of life of someone who is
dead. Nor does it seem much better to speculate about
what their symptoms or problems would have been if
they had not died or assuming that the imputed score
for a dead person could equally apply to a living person.
The consequence of leaving out those who died is that
one can argue that our primary analysis investigates the
effect of SPC on the primary needs of those who are
alive eight weeks after randomization only. However, we
argue that it is only relevant to investigate the effect of
SPC on the primary need of those who are alive. Or, to
argue the other way round, if patients who die shortly
after inclusion differ from other patients on certain base-
line characteristics (which is not unlikely) and if we in-
clude the data from these patients (for whom it did not
become relevant) in the estimation of the primary out-
come, then such a result would be extremely difficult to
interpret clinically. Note, however, that patients who
died during the trial are included in a sensitivity analysis.
The risk of leaving out the patients who died is that
one may overestimate the effect of the experimental
intervention if there is a difference in mortality in the
two groups and the experimental intervention group has
the highest mortality (it could also be the other way
around). We will therefore conduct a sensitivity analysis
including the patients who died, and we will consider
the risks of serious adverse events when interpreting the
primary outcome as described in the section on ‘signifi-
cance’. If the primary analyses yield results that are very
different from the sensitivity analysis, we will include
further relevant sensitivity analyses.
Missing data due to nonresponse
Trials in palliative care cannot avoid the problems of
missing data due to nonresponders. Our basic assump-
tion is that the missing data are missing at random
(MAR), and that nonresponse is not related to the
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our knowledge from working with this group of patients:
there are many reasons for nonresponse that are not re-
lated to the effects of intervention. These patients are
frequently hospitalized, they may suddenly get more ill,
they are frail, they may get problems concentrating and
so forth. In addition, the mechanisms causing nonre-
sponse are also likely to be evident from the assessments
that are not missing, For example, patients who are non-
responders due to impaired cognitive function are likely
to have a worse cognitive function at baseline [25].Number of secondary outcomes and multiplicity
In this trial, we have more secondary outcomes than is
often recommended [16]. However, all of them are highly
relevant when evaluating SPC. Further, there may be con-
cern about the interpretation of our primary outcome
because this outcome has never been used before. We
believe that it will enhance the transparency of the tri-
al’s primary outcome to analyze each of the scales rep-
resented in the primary outcome for all patients as a
secondary outcome analysis.
To adjust for the familywise error, we considered using
the Bonferroni or the Holm’s corrections [15]. However,
both corrections are too conservative when working
with correlated outcomes [16]. To achieve what we be-
lieve to be a more fair balance between type I and type
II errors, we choose an alpha level of 0.01 for the sec-
ondary outcomes. With an alpha of 0.01, nine independ-
ent tests (although we are aware that not all of the tests
are independent), and no true group difference, then the
risk of at least one familywise type I error (to wrongly
conclude that there is a difference for at least one sec-
ondary outcome) is 9%. The risk of making two or more
such type I errors is at a marginal level of 0.3%.
With an alpha of 0.01, nine independent tests, and a
true group difference with an effect size of 0.4, the risk
of at least one type II error (to wrongly conclude that
there is no difference for at least one secondary out-
come) is 85%. The risk of making two or more such type
II errors is 54%. Hence, with a lower alpha level, these
type II errors were deemed too high.Not stratified by center
It is nearly always considered good practice to stratify by
center in a multi-center trial, because one will expect
that patients from the same center have a higher intra-
class coefficient [21]. To reduce the risk of overstratifica-
tion, we have chosen not to stratify by center in DanPaCT.
We believed it to be more important to stratify for primary
need as patients having the same primary symptom or
problem may be more similar, and the effect of SPC may
vary across symptoms or problems.Area under the curve
There are some variations in the actual time points of
when the outcomes were measured. For some patients
longer times elapsed before they received and filled in
the questionnaires than for others. It could be interest-
ing to use real-time data in the weighting of the out-
comes, because ‘time’ could be a factor that influences
effect. However, if we used the actual number of days
elapsing, then the area under the curve (AUC) for two
patients having the same symptom burden would be lar-
ger for the person who participated in the trial the lon-
gest. To prevent this, one could divide the AUC with the
number of weeks the patient was participating to get
AUC per week. However, as we do not expect the mag-
nitude of effect to be linearly related to length of trial
participation [26], we decided to use the same fixed
weighting for the three- and eight-week follow-up for all
patients.
We also considered whether the AUC should include
the time that passed from baseline to randomization.
However, as the events happening in this time period
have nothing to do with group assignment (the patients
were not randomized yet) we decided that the AUC
starts at randomization.
Changes from the original protocol
We made the following changes: 1) Originally, we had
too many secondary outcomes, and therefore several of
these have been reduced to exploratory outcomes. This
was decided during the process of writing this SAP.
2) We have adjusted the P values further to control for
the familywise error. 3) In the protocol, we were to test
for differences in marital status and comorbidity between
the two groups. These data have not been collected and
these analyses will, therefore, not be made. 4) In the im-
putation model, we wrote that we would include cancer
stage. However, all patients have stage four, so this is not
necessary. We also changed the criteria as to how vari-
ables will be chosen for the imputation model. 5) In the
Danish version of the protocol, we described a sensitivity
analysis that has now been excluded. In that analysis, we
would make a worst-case-scenario analysis where all miss-
ing data in the intervention group were substituted with
the worst possible score, and all missing data in the con-
trol group were substituted with the best possible score.
Some sensitivity analyses have been added and the covari-
ates included in the first sensitivity analysis have been
changed. 6) Several details have been added.
Interpretation of the evidence and considerations on
implementation in clinical practice
In order to guide potential future implementation in clin-
ical practice, the results of the DanPaCT project should be
analyzed in a systematic review including meta-analyses
Johnsen et al. Trials 2014, 15:376 Page 9 of 10
http://www.trialsjournal.com/content/15/1/376and trial sequential analyses of all relevant randomized
clinical trials based on a public protocol for the systematic
review [27-31]. Preferably, the analyses should be based on
depersonalized individual patient data [27].
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